PLYMOUTH, Minn., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis, nasal airway obstruction and persistent Eustachian tube dysfunction, today reported its financial results for the quarter ended June 30, 2017.
Recent Highlights and Accomplishments
•Revenue of $22.1 million in the second quarter of 2017, an increase of 18% over same quarter last year
Recent Highlights and Accomplishments
•Revenue of $22.1 million in the second quarter of 2017, an increase of 18% over same quarter last year
